Anavex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. 

CEO
Christopher U. Missling
CEOChristopher U. Missling
Employees
34
Employees34
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2004
Founded2004
Employees
34
Employees34

AVXL Key Statistics

Market cap
350.69M
Market cap350.69M
Price-Earnings ratio
-7.39
Price-Earnings ratio-7.39
Dividend yield
Dividend yield
Average volume
2.54M
Average volume2.54M
High today
$4.09
High today$4.09
Low today
$3.81
Low today$3.81
Open price
$3.97
Open price$3.97
Volume
2.71M
Volume2.71M
52 Week high
$14.44
52 Week high$14.44
52 Week low
$2.86
52 Week low$2.86

Stock Snapshot

With a market cap of 350.69M, Anavex(AVXL) trades at $3.93. The stock has a price-to-earnings ratio of -7.39.

During the trading session on 2025-12-17, Anavex(AVXL) shares reached a daily high of $4.09 and a low of $3.81. At a current price of $3.93, the stock is +3.2% higher than the low and still -4.0% under the high.

Trading activity shows a volume of 2.71M, compared to an average daily volume of 2.54M.

Over the past 52 weeks, Anavex(AVXL) stock has traded between a high of $14.44 and a low of $2.86.

Over the past 52 weeks, Anavex(AVXL) stock has traded between a high of $14.44 and a low of $2.86.

AVXL News

TipRanks 10h
Promising Therapeutic Potential of Blarcamesine Sparks Buy Rating for Anavex Life Sciences

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences and keeping the price target at $20.00. Claim 50% Off TipRanks Premiu...

TipRanks 5d
Anavex announces negative CHMP opinion on blarcamesine MAA

Anavex (AVXL) provided an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer’s disease. As per previous communication, the Euro...

People also own

Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.